Literature DB >> 12429581

Effects of the selective inhibition of platelet thromboxane synthesis on the platelet-subendothelium interaction.

J P De La Cruz1, M A Villalobos, R Escalante, A Guerrero, M M Arrebola, F Sánchez de La Cuesta.   

Abstract

1. Drugs that inhibit TxA(2) synthesis are used to reduce platelet aggregation. The aim of this study was to compare the effects of a cyclo-oxygenase (COX) inhibitor (acetylsalicylic acid, ASA), a thromboxane synthetase (TxS) inhibitor (dazoxiben) and a dual TxS inhibitor and TxA(2) receptor blocker (DT-TX 30) on platelet aggregation and the platelet-subendothelium interaction in flow conditions. 2. The techniques used in this in vitro study were platelet aggregometry in whole blood, and measurement of platelet thromboxane B(2) and prostaglandin E(2) production and leucocyte production of 6-keto-PGF(1alpha). The platelet-subendothelium interaction was evaluated in rabbit aorta subendothelium preparations exposed to flowing blood at a shear stress of 800 s(-1). Morphometric methods were used to calculate the percentage of subendothelium occupied by platelets. 3. The 50% inhibitory concentration (IC(50)) of DT-TX 30 in whole blood was in the range of 10(-7) micro M (induced with collagen or arachidonic acid) to 10(-5) micro M (induced with thrombin) or 10(-4) (induced with ADP). IC(50) values under all experimental conditions were lower with DT-TX 30 than with ASA. For thromboxane B(2) the IC(50) were: ASA 0.84+/-0.05 micro M, dazoxiben 765+/-54 micro M, DT-TX 30 8.54+/-0.60 micro M. Prostaglandin E(2) was inhibited only by ASA (IC(50) 1.21+/-0.08 micro M). Leucocyte 6-keto-PGF(1alpha) was inhibited by ASA (IC(50) 6.58+/-0.76 micro M) and increased by dazoxiben and DT-TX 30. The greatest reduction in percentage subendothelial surface occupied by platelets after blood perfusion was seen after treatment with DT-TX 30 in the range of concentrations that inhibited collagen-induced platelet aggregation (control group: 31.20+/-3.8%, DT-TX 30 at 0.1 micro M: 10.71+/-0.55%, at 1.0 micro M: 6.53+/-0.44%, at 5.0 micro M; 1.48+/-0.07%). All three drugs reduced thrombus formation, although ASA (unlike dazoxiben or DT-TX 30) increased the percentage surface occupied by adhesions. 4. In conclusion, the effect of specific blockage of TxS together with blockage of membrane receptors for TxA(2) can surpass the effect of ASA in inhibiting the platelet-subendothelium interaction in flow conditions.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12429581      PMCID: PMC1573583          DOI: 10.1038/sj.bjp.0704963

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  27 in total

1.  DTTX30, a combined thromboxane receptor antagonist and thromboxane synthetase inhibitor, prevents coronary thrombosis in anesthetized dogs.

Authors:  B D Guth; T H Müller
Journal:  Basic Res Cardiol       Date:  1997-06       Impact factor: 17.165

2.  Effect of aspirin on prostanoids and nitric oxide production in streptozotocin-diabetic rats with ischemic retinopathy.

Authors:  P De La Cruz; A Guerrero; J Paniego; I Arranz; A Moreno; F Sánchez De La Cuesta
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2001-12-14       Impact factor: 3.000

3.  Effect of DT-TX 30, a combined thromboxane synthase inhibitor and thromboxane receptor antagonist, on retinal vascularity in experimental diabetes mellitus.

Authors:  J P De La Cruz; A Moreno; M I Ruiz-Ruiz; F Sánchez De La Cuesta
Journal:  Thromb Res       Date:  2000-02-01       Impact factor: 3.944

4.  Adhesion of platelets to subendothelium.

Authors:  H R Baumgartner; C Haudenschild
Journal:  Ann N Y Acad Sci       Date:  1972-10-27       Impact factor: 5.691

5.  Effect of dipyridamole and aspirin on the platelet-neutrophil interaction via the nitric oxide pathway.

Authors:  J P De La Cruz; E Blanco; F Sánchez de la Cuesta
Journal:  Eur J Pharmacol       Date:  2000-05-26       Impact factor: 4.432

Review 6.  Methods and models to evaluate shear-dependent and surface reactivity-dependent antithrombotic efficacy.

Authors:  K S Sakariassen; S R Hanson; Y Cadroy
Journal:  Thromb Res       Date:  2001-11-01       Impact factor: 3.944

7.  Inhibition of platelet-vessel wall interactions by thromboxane receptor antagonism in a human in vitro system: potentiation of antiplatelet effects of aspirin.

Authors:  G Escolar; M Albors; M Garrido; G Bioque; M Díaz Ricart; M Carretero; A Ordinas
Journal:  Eur J Clin Invest       Date:  1998-07       Impact factor: 4.686

8.  Effects of aspirin on platelet-neutrophil interactions. Role of nitric oxide and endothelin-1.

Authors:  A López-Farré; C Caramelo; A Esteban; M L Alberola; I Millás; M Montón; S Casado
Journal:  Circulation       Date:  1995-04-01       Impact factor: 29.690

9.  Pulmonary pharmacology of DT-TX 30 SE, a potent selective combined thromboxane synthetase inhibitor and receptor antagonist, in guinea pigs.

Authors:  C J Meade; G Muacevic; P Ward; R Soyka
Journal:  Jpn J Pharmacol       Date:  1996-06

10.  Residual platelet function under acetylsalicylic acid and the risk of restenosis after coronary angioplasty.

Authors:  W Terres; C W Hamm; A Ruchelka; A Weilepp; W Kupper
Journal:  J Cardiovasc Pharmacol       Date:  1992-02       Impact factor: 3.105

View more
  1 in total

1.  Licochalcones extracted from Glycyrrhiza inflata inhibit platelet aggregation accompanied by inhibition of COX-1 activity.

Authors:  Asa Okuda-Tanino; Daiki Sugawara; Takumi Tashiro; Masaya Iwashita; Yutaro Obara; Takahiro Moriya; Chisato Tsushima; Daisuke Saigusa; Yoshihisa Tomioka; Kuniaki Ishii; Norimichi Nakahata
Journal:  PLoS One       Date:  2017-03-10       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.